arrow
J

Joseph A. Fraietta

Abramson Cancer Center
H指数:45
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion

可编程CAR-结合颗粒重编程人CAR T细胞信号以实现可持续体外扩增

2026-09-070
OAAI
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

出版更正:CD19 CAR T细胞在B细胞淋巴瘤中的十年持久性

2026-08-260
OAAI
A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection

模块化 γ δ tcr-t平台,将KRAS pMHC靶向与可重复剂量的mRNA接合器重定向相结合

2026-07-300
OA
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy

初始CD4+ T细胞和CART输注时的疾病状态与接受二线CAR T疗法的大B细胞淋巴瘤患者的真实世界临床结局相关

2026-05-150
OAAI
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer

泛血液学癌症对嵌合抗原受体 (CAR) T细胞治疗反应的预测生物标志物

2026-03-090
PRE
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy

CD4 T细胞介导BCMA car-t细胞治疗后car-t细胞相关的免疫相关不良事件

2026-01-150
PRE
Outcomes of relapse after teclistamab therapy in multiple myeloma

接受特昔利珠单抗治疗后多发性骨髓瘤复发的结局

2025-11-050
OAAI
Immune remodeling in CSF and tumor predicts response to CAR T therapy in glioblastoma

脑脊液和肿瘤中的免疫重塑预测胶质母细胞瘤对CAR T疗法的反应

2025-11-010
OAAI
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy

CCR5靶向的异基因γ-δ CD19嵌合抗原受体T细胞用于HIV相关B细胞恶性免疫治疗

2025-10-210
PRE
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer

胰腺癌中CAR T细胞耐药性的临床与分子解析

2025-08-180
OAAI
TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function
2024-11-150
OAAI
Efficacy and Safety of Anti-CDI9 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

抗CDI9和抗BCMA嵌合抗原受体(CAR)T细胞疗法在自身免疫性疾病、淋巴瘤或骨髓瘤患者中的疗效与安全性

BLOOD
IF23.1
2024-11-050
PRE
Cytokine-mediated CAR T therapy resistance in AML

细胞因子介导的AML car-t治疗耐药

2024-09-272
PRE
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia

CD19 CAR T细胞回输预防和治疗儿童急性淋巴细胞白血病复发

2024-04-291
OAAI